272 related articles for article (PubMed ID: 24098585)
1. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
Vieria Neto L; Wildemberg LE; Colli LM; Kasuki L; Marques NV; Moraes AB; Gasparetto EL; Takiya CM; Castro M; Gadelha MR
PLoS One; 2013; 8(10):e77406. PubMed ID: 24098585
[TBL] [Abstract][Full Text] [Related]
2. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.
Neto LV; Machado Ede O; Luque RM; Taboada GF; Marcondes JB; Chimelli LM; Quintella LP; Niemeyer P; de Carvalho DP; Kineman RD; Gadelha MR
J Clin Endocrinol Metab; 2009 Jun; 94(6):1931-7. PubMed ID: 19293270
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas.
Taboada GF; Luque RM; Bastos W; Guimarães RF; Marcondes JB; Chimelli LM; Fontes R; Mata PJ; Filho PN; Carvalho DP; Kineman RD; Gadelha MR
Eur J Endocrinol; 2007 Jan; 156(1):65-74. PubMed ID: 17218727
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
Horiguchi K; Yamada M; Umezawa R; Satoh T; Hashimoto K; Tosaka M; Yamada S; Mori M
Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
[TBL] [Abstract][Full Text] [Related]
5. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
6. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas.
Mayr B; Buslei R; Theodoropoulou M; Stalla GK; Buchfelder M; Schöfl C
Eur J Endocrinol; 2013 Oct; 169(4):391-400. PubMed ID: 23847328
[TBL] [Abstract][Full Text] [Related]
7. Differential gene expression of sirtuins between somatotropinomas and nonfunctioning pituitary adenomas.
Grande IPP; Amorim PVGH; Freire ACTB; Jallad RS; Musolino NR; Cescato VA; da Silva GO; Bronstein MD; Trarbach EB
Pituitary; 2018 Aug; 21(4):355-361. PubMed ID: 29564694
[TBL] [Abstract][Full Text] [Related]
8. Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study.
Ramírez C; Cheng S; Vargas G; Asa SL; Ezzat S; González B; Cabrera L; Guinto G; Mercado M
J Clin Endocrinol Metab; 2012 May; 97(5):1745-51. PubMed ID: 22419713
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin receptor subtype gene expression in pituitary adenomas.
Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
[TBL] [Abstract][Full Text] [Related]
11. Study of major genetic factors involved in pituitary tumorigenesis and their impact on clinical and biological characteristics of sporadic somatotropinomas and non-functioning pituitary adenomas.
Foltran RK; Amorim PVGH; Duarte FH; Grande IPP; Freire ACTB; Frassetto FP; Dettoni JB; Alves VA; Castro I; Trarbach EB; Bronstein MD; Jallad RS
Braz J Med Biol Res; 2018 Jun; 51(9):e7427. PubMed ID: 29947650
[TBL] [Abstract][Full Text] [Related]
12. Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas.
Luque RM; Ibáñez-Costa A; Neto LV; Taboada GF; Hormaechea-Agulla D; Kasuki L; Venegas-Moreno E; Moreno-Carazo A; Gálvez MÁ; Soto-Moreno A; Kineman RD; Culler MD; Gahete MD; Gadelha MR; Castaño JP
Cancer Lett; 2015 Apr; 359(2):299-306. PubMed ID: 25637790
[TBL] [Abstract][Full Text] [Related]
13. Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas.
Padova H; Rubinfeld H; Hadani M; Cohen ZR; Nass D; Taylor JE; Culler MD; Shimon I
Mol Cell Endocrinol; 2008 May; 286(1-2):214-8. PubMed ID: 18276067
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles.
Coelho MCA; Vasquez ML; Wildemberg LE; Vázquez-Borrego MC; Bitana L; Camacho AHDS; Silva D; Ogino LL; Ventura N; Sánchez-Sánchez R; Chimelli L; Kasuki L; Luque RM; Gadelha MR
Sci Rep; 2019 Feb; 9(1):1122. PubMed ID: 30718563
[TBL] [Abstract][Full Text] [Related]
15. Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry.
Wildemberg LE; Vieira Neto L; Costa DF; Nasciutti LE; Takiya CM; Alves LM; Gadelha MR
J Endocrinol Invest; 2012 Jun; 35(6):580-4. PubMed ID: 21897115
[TBL] [Abstract][Full Text] [Related]
16. Impact of gsp oncogene on the mRNA content for somatostatin and dopamine receptors in human somatotropinomas.
Taboada GF; Neto LV; Luque RM; Córdoba-Chacón J; de Oliveira Machado E; de Carvalho DP; Kineman RD; Gadelha MR
Neuroendocrinology; 2011; 93(1):40-7. PubMed ID: 21079388
[TBL] [Abstract][Full Text] [Related]
17. Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo.
Nielsen S; Mellemkjaer S; Rasmussen LM; Ledet T; Olsen N; Bojsen-Møller M; Astrup J; Weeke J; Jørgensen JO
J Endocrinol Invest; 2001 Jun; 24(6):430-7. PubMed ID: 11434667
[TBL] [Abstract][Full Text] [Related]
18. BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma.
Shi C; Ye Z; Han J; Ye X; Lu W; Ji C; Li Z; Ma Z; Zhang Q; Zhang Y; He W; Chen Z; Cao X; Shou X; Zhou X; Wang Y; Zhang Z; Li Y; Ye H; He M; Chen H; Cheng H; Sun J; Cai J; Huang C; Ye F; Luo C; Zhou B; Ding H; Zhao Y
Neuro Oncol; 2020 Aug; 22(8):1114-1125. PubMed ID: 32246150
[TBL] [Abstract][Full Text] [Related]
19. Somatotropinomas, but not nonfunctioning pituitary adenomas, maintain a functional apoptotic RET/Pit1/ARF/p53 pathway that is blocked by excess GDNF.
Diaz-Rodriguez E; Garcia-Rendueles AR; Ibáñez-Costa A; Gutierrez-Pascual E; Garcia-Lavandeira M; Leal A; Japon MA; Soto A; Venegas E; Tinahones FJ; Garcia-Arnes JA; Benito P; Angeles Galvez M; Jimenez-Reina L; Bernabeu I; Dieguez C; Luque RM; Castaño JP; Alvarez CV
Endocrinology; 2014 Nov; 155(11):4329-40. PubMed ID: 25137025
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance spectroscopy may serve as a presurgical predictor of somatostatin analog therapy response in patients with growth hormone-secreting pituitary macroadenomas.
Hu J; Yan J; Zheng X; Zhang Y; Ran Q; Tang X; Shu T; Shen R; Duan L; Zhang D; Guo Q; Zhang W; Yang H; Li S
J Endocrinol Invest; 2019 Apr; 42(4):443-451. PubMed ID: 30171531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
